2025-682-E-Health Dept-Pharmalink-Pharmaceutical drug return and destruction services

Browse Search

6 CONFIDENTIAL 11122019 (“ERV”) is for reporting purposes only. PLI DOES NOT WARRANT OR GUARANTEE A SPECIFIC REFUND METHOD OR CREDIT AMOUNT FROM THE MANUFACTURER. 3. Your wholesaler may have contracted with PLI to utilize “batch processing,” an industry standard process, to maximize efficiency, credit value and expedite the manufacturer’s credit process. Batch processing may require the Customer’s product to be intermingled with product from other customers for shipment to the manufacturer. As a result, the Customer’s credits may be: (1) pro-rated based on the percentage of the Customer’s product included in the shipment to the manufacturer, (2) subject to the wholesaler’s administration fee, and (3) vary in value per return. A manufacturer may elect not to participate in a batch return program. Products that PLI determines credit eligible, based on the manufacturer’s return policy criteria, shall be returned directly to the manufacturer or their agent. PLI shall invoice the Customer separately. PLI’s Service fees shall be based on ERV and equivalent to the SOW agreed upon percentage rate. Invoice shall be due upon receipt. 4. Customer will receive a list of all returnable and non-returnable Goods and a non-binding credit estimate. All credit estimates and Services procedures are determined by strict participants’ returns policies and PLI's proprietary pricing files. The Customer facility will receive credit directly from the Customer’s participating wholesaler or PLI for the manufacturer’s determined credit value, less Services fees payable to PLI. PLI service fees will be deducted from the Customer’s actual credits. If Customer receives a Direct Credit from the Manufacturer or PLI’s Service fees cannot be deducted from a Customer’s return credits, PLI shall issue an invoice for minimum amounts due, services rendered, spill and environment surcharge fees to Customer for payment. PLI reserves the right to accommodate Customers’ billing practices to include Customers’ handling/processing/drop ship credit fees as an item separate from the fee for the Services. 5. Goods deemed non-returnable or non-creditable shall be destroyed in accordance with the laws governing such destruction and shall be manifested accordingly. Disposal fees, including minimum amount due will be invoiced directly to the Customer. 6. PLI will accept waste as defined under the term “viable” as defined in this Agreement. Any waste received according to the viable definition will be disposed of according to applicable federal, state, and local guidelines and charged per pound, regardless of controlled schedule. PLI will provide a certificate of destruction within thirty (30) days of receipt of product and after the product has been properly destroyed. 7. This Contract is not a hazardous waste disposal contract and therefore, PLI will not knowingly accept non-creditable hazardous waste for processing. In the event PLI does either inadvertently accept or later discovers a product is non-creditable hazardous waste, PLI will process the non-creditable hazardous pharmaceutical product according to applicable federal, state, and local hazardous pharmaceutical waste requirements. 8. The Hazardous Waste Fee will pertain to all RCRA listed waste and other waste that requires special handling and must be disposed of as hazardous waste. 9. Beginning January 1, 2020 and every January 1st thereafter PLI’s waste disposal fees will increase annually at a rate of 5% to cover the increased cost of pharmaceutical incineration disposal. 10. PLI shall not be liable if any credit eligible product is received by PLI in returnable condition and subsequently damaged or lost in transit or while in possession of PLI. 11. Any Goods that are returned to PLI for processing from the 340B Drug Pricing Program, Patient Assistance Programs (PAP), charitable donation, humanitarian aid, or any other discount program must Docusign Envelope ID: 550F0A34-DEE8-4FFA-B72D-1ABBE467C60B